Trilogy Capital Inc. Takes Position in Insulet Co. (NASDAQ:PODD)

Trilogy Capital Inc. acquired a new position in shares of Insulet Co. (NASDAQ:PODD - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,753 shares of the medical instruments supplier's stock, valued at approximately $2,024,000.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Blue Trust Inc. boosted its position in Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 58 shares during the last quarter. Venturi Wealth Management LLC raised its stake in Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after buying an additional 133 shares during the period. Friedenthal Financial bought a new stake in Insulet in the fourth quarter valued at approximately $57,000. TD Private Client Wealth LLC raised its stake in Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock valued at $53,000 after buying an additional 56 shares during the period. Finally, Versant Capital Management Inc raised its stake in Insulet by 106.1% in the fourth quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier's stock valued at $80,000 after buying an additional 157 shares during the period.

Analysts Set New Price Targets

PODD has been the topic of several research analyst reports. Raymond James upped their price objective on Insulet from $213.00 to $260.00 and gave the company an "outperform" rating in a research note on Monday, October 14th. Morgan Stanley upped their price objective on Insulet from $234.00 to $317.00 and gave the company an "overweight" rating in a research note on Monday, November 11th. Canaccord Genuity Group upped their price objective on Insulet from $269.00 to $304.00 and gave the company a "buy" rating in a research note on Monday, December 9th. TD Cowen upped their price objective on Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a research note on Friday, January 3rd. Finally, BTIG Research increased their target price on Insulet from $260.00 to $270.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $277.13.

Insider Activity

In other news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Lauren Budden sold 915 shares of the business's stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company's stock.

Insulet Price Performance

NASDAQ:PODD traded up $2.62 during trading hours on Monday, reaching $285.70. 133,346 shares of the company were exchanged, compared to its average volume of 514,187. The company has a market capitalization of $20.04 billion, a P/E ratio of 48.91, a P/E/G ratio of 3.61 and a beta of 1.23. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The business has a 50 day moving average of $270.27 and a 200 day moving average of $241.58.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.77 by $0.13. Insulet had a return on equity of 27.98% and a net margin of 21.22%. The business had revenue of $543.90 million for the quarter, compared to the consensus estimate of $518.50 million. During the same quarter in the prior year, the business posted $0.71 earnings per share. Research analysts forecast that Insulet Co. will post 3.22 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.